International Journal of Medicine and Medical Sciences

International Journal of Medicine and Medical Sciences | Vol. 1, No. 1, January 2026 | pp. 1–8

DOI: 10.14303/oajc.2026.001

Original Research Article

Efficacy of Novel Beta-Blockers in Reducing Left Ventricular Hypertrophy: A Randomized Controlled Trial

Alexander Vance¹*

¹Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract:

Left ventricular hypertrophy (LVH) is a major independent predictor of myocardial infarction, heart failure, and sudden cardiac death, necessitating aggressive therapeutic regression. This prospective, randomized, double-blind, active-controlled, parallel-group trial evaluated the efficacy of nebivolol-X, a novel third-generation beta-blocker with nitric oxide-mediated vasodilatory properties, versus standard metoprolol succinate. A total of 350 hypertensive patients (aged 18–75 years) with baseline echocardiographically confirmed LVH (left ventricular mass index [LVMI] ≥ 115 g/m² for men, ≥ 95 g/m² for women) were randomized 1:1 to receive either nebivolol-X (5–10 mg/day, n = 175) or metoprolol succinate (50–100 mg/day, n = 175) over a 12-month period. The primary endpoint was the absolute change in LVMI quantified by 1.5-Tesla Cardiac Magnetic Resonance Imaging (CMR). Secondary endpoints included applanation tonometry-derived central aortic systolic blood pressure (CASBP), carotid-femoral pulse wave velocity (cfPWV), and brachial artery flow-mediated dilation (FMD). Analysis was performed on an intent-to-treat basis using Analysis of Covariance (ANCOVA). At 12 months, the nebivolol-X cohort demonstrated a highly significant reduction in mean LVMI from 124.6 ± 12.3 g/m² to 106.2 ± 10.1 g/m² (net change: -18.4 g/m²), whereas the metoprolol cohort decreased from 123.9 ± 11.8 g/m² to 113.7 ± 10.9 g/m² (net change: -10.2 g/m²), yielding a significant intergroup difference favoring nebivolol-X (-8.2 g/m²; 95% Confidence Interval [CI]: -11.4 to -5.0; p < 0.01). While peripheral brachial blood pressure reductions were uniform between arms (p = 0.22), nebivolol-X produced superior adjustments in CASBP (-14.2 ± 3.2 mmHg vs. -8.1 ± 2.9 mmHg; p < 0.01) and cfPWV (-1.4 m/s vs. -0.3 m/s; p < 0.01). Endothelial function via FMD improved by an absolute +3.2% ± 0.8% with nebivolol-X but worsened by -0.1% ± 0.4% with metoprolol (p < 0.001). Adverse events including sinus bradycardia (4.5% vs. 11.4%; p = 0.02) and fatigue (6.8% vs. 14.8%; p = 0.01) were lower with nebivolol-X. In conclusion, nebivolol-X achieves superior regression of hypertensive left ventricular hypertrophy compared to metoprolol. This benefit is driven by reduced wave reflections and improved endothelial function via nitric oxide pathways rather than simple peripheral blood pressure lowering, representing a distinct clinical advantage for long-term cardioprotection.

Keywords: Left ventricular hypertrophy, Beta-blockers, Hypertension, Cardiac magnetic resonance imaging, Nitric oxide, Endothelial function, Central hemodynamics

Manuscript Timeline: Received: September 12, 2025; Revised: November 04, 2025; Accepted: December 01, 2025; Published: January 15, 2026.

Citation: Vance A. Efficacy of Novel Beta-Blockers in Reducing Left Ventricular Hypertrophy: A Randomized Controlled Trial. International Journal of Medicine and Medical Sciences, 2026, 1(1): 1–8. DOI: 10.14303/oajc.2026.001